Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumors 11Mesothelioma, Malignant 8Solid Tumor 6Advanced Solid Tumor 6Mesothelioma 3Melanoma 3Carcinoma, Renal Cell 3Carcinoma, Non-Small-Cell Lung 3Advanced Solid Tumors 3Treatment-Refractory Solid Tumors 2Squamous Cell Carcinoma of Head and Neck 2Carcinoma, Merkel Cell 2Wilms Tumor 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Solid Tumour 1Solid Tumor, Adult 1Small Cell Lung Carcinoma 1Select Advanced Solid Tumors 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Locally Advanced or Metastatic Solid Tumors 1Locally Advanced Solid Tumors 1Locally Advanced Solid Tumor 1Kidney Neoplasms 1Head and Neck Neoplasms 1HER2-positive Breast Cancer 1Gastrointestinal Neoplasms 1

Interventions

tebentafusp 1pembrolizumab 1fludarabine 1atezolizumab 1Interleukin-2 1Drug Therapy 1Cyclophosphamide 1Bevacizumab 1Antibodies, Monoclonal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Select Advanced Solid Tumors × atezolizumab × Other solid neoplasm × Clear all
NCT03973333 2024-10-18

Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Immunocore Ltd

Phase 1/2 Withdrawn
Other solid neoplasm

Select Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡